Systemic Pharmacokinetics And Pharmacodynamics Of Intravitreal Aflibercept, Bevacizumab, And Ranibizumab

Robert L. Avery,Alessandro A. Castellarin,Nathan Steinle,Dilsher Dhoot,Dante J. Pieramici,Robert F. See,Stephen Couvillion,Maʼan A. Nasir,Melvin Rabena,Mauricio Maia,Sherri Van Everen,Kha Le,William D. Hanley

Systemic Pharmacokinetics And Pharmacodynamics Of Intravitreal Aflibercept, Bevacizumab, And Ranibizumab

2017

Robert L. Avery
Alessandro A. Castellarin
Nathan Steinle
Dilsher Dhoot
Dante J. Pieramici
Robert F. See
Stephen Couvillion
Maʼan A. Nasir
Melvin Rabena
Mauricio Maia
Sherri Van Everen
Kha Le
William D. Hanley

Purpose:To evaluate the systemic pharmacokinetics (PKs) of aflibercept, bevacizumab, and ranibizumab in patients with neovascular age-related macular degeneration (AMD), diabetic macular edema (DME), or retinal vein occlusion (RVO).Methods:Prospective, open-label, nonrandomized clinical trial of pat

Keywords:

Ranibizumab
Macular degeneration
Surgery
Bevacizumab
Clinical trial
Aflibercept
Macular edema
Medicine
Retinal Vein
Pharmacokinetics
Diabetes mellitus

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

135

Citations